KVUE
Kenvue (KVUE) rose 2% after the FDA approved Tylenol with Naproxen, a new over-the-counter pain reliever...
Article Summary
HOLD- Kenvue (KVUE) rose 2% after the FDA approved Tylenol with Naproxen, a new over-the-counter pain reliever that pairs 650 mg of acetaminophen with 220 mg of naproxen sodium in a single dose, beginning working in under 30 minutes and providing up to 12 hours of pain relief.
- The FDA granted Kenvue three years of exclusivity for the new formulation, with the drug expected to be available soon at major U.S. retailers nationwide.
- The green light arrives despite continued pressure on the Tylanol brand, with President Donald Trump and members of his administration claiming acetamophen use during pregnancy may be linked to autism in September 2025, urging pregnant women to avoid the drug.
- The comments triggered a sharp drop in KenvUE's stock at the time and drew widespread pushback from doctors, medical groups and international health agencies who said the science does not support a causal link.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | -0.1% | 25% | 0.0 ptsDeclining (-0.1%) - NOT a growth stock |
| EPS Growth Next 5Y ? | 7.2% | 25% | 20.0 ptsWeak (7.2%) - Low expectations |
| Target Price Upside ? | 2.2% | 20% | 20.0 ptsMinimal Upside (2.2%) - Target: $19.70 vs Current: $19.28 |
| Gross Margin % ? | 58.4% | 15% | 80.0 ptsVery Healthy (58.4%) - High-quality margins |
| Drawdown from 52-Wk High ? | -15.7% | 15% | 40.0 ptsMild Pullback (-15.7%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About KVUE
- Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.
- It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health.
- The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements.
- It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands.
- Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.